Not applicableNo Longer AvailableNCT04453397What this trial is testingExpanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma TeneoOne Inc.
Very early researchLooking for participantsNCT07493135What this trial is testingIMV102 in Patients With Relapsed/Refractory Multiple MyelomaWho this might be right forRelapsed/Refractory Multiple Myeloma Suzhou Immunofoco Biotechnology Co., Ltd 30
Testing effectiveness (Phase 2)Study completedNCT01745640What this trial is testingPomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)Who this might be right forMultiple Myeloma University Hospital, Lille 63
Testing effectiveness (Phase 2)UnknownNCT00800059What this trial is testingTotal Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory MyelomaWho this might be right forMultiple Myeloma Ottawa Hospital Research Institute 27
Early research (Phase 1)Ended earlyNCT02978235What this trial is testingA Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaWho this might be right forMultiple MyelomaNonHodgkin Lymphoma Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Ended earlyNCT05117008What this trial is testingMaintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRefractory Multiple MyelomaRelapse Multiple Myeloma Medical College of Wisconsin 1
Early research (Phase 1)Study completedNCT03733717What this trial is testingEvaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Sanofi 25
Testing effectiveness (Phase 2)Ended earlyNCT03201250What this trial is testingCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaWho this might be right forMultiple MyelomaRefractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma University of Nebraska 11
Testing effectiveness (Phase 2)UnknownNCT01886976What this trial is testingTreatment of Chemotherapy Refractory Multiple Myeloma by CART-138Who this might be right forMultiple Myeloma Chinese PLA General Hospital 10
Early research (Phase 1)UnknownNCT03674463What this trial is testingLCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple MyelomaWho this might be right forRefractory or Relapsed Multiple Myeloma Second Affiliated Hospital of Xi'an Jiaotong University 10
Early research (Phase 1)Ended earlyNCT04892264What this trial is testingBelantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaWho this might be right forPlasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Mayo Clinic 5
Large-scale testing (Phase 3)Looking for participantsNCT07579234What this trial is testingA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma (RRMM) Shandong New Time Pharmaceutical Co., LTD 261
Testing effectiveness (Phase 2)Study completedNCT04205409What this trial is testingNivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesWho this might be right forRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more University of Washington 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03556332What this trial is testingCarfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationWho this might be right forMultiple Myeloma Memorial Sloan Kettering Cancer Center 41
Early research (Phase 1)UnknownNCT03751293What this trial is testingBCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Hebei Yanda Ludaopei Hospital 10
Early research (Phase 1)Study completedNCT02095834What this trial is testingCarfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma M.D. Anderson Cancer Center 18
Early research (Phase 1)Active Not RecruitingNCT05666700What this trial is testingCAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring StudyWho this might be right forExtramedullary Myeloma Peter MacCallum Cancer Centre, Australia 10
Testing effectiveness (Phase 2)Study completedNCT03731832What this trial is testingPomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple MyelomaWho this might be right forRefractory Multiple Myeloma GWT-TUD GmbH 66
Testing effectiveness (Phase 2)Study completedNCT02963493What this trial is testingMelphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Oncopeptides AB 157
Early research (Phase 1)Not Yet RecruitingNCT07720843What this trial is testingTAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Who this might be right forRelapse Multiple MyelomaRefractory Multiple Myeloma Montefiore Medical Center 50